Special Issues
Table of Content

Targeting the Tumor Microenvironment: Emerging Insights into Cancer Progression and Therapeutics

Submission Deadline: 30 April 2026 View: 929 Submit to Special Issue

Guest Editors

Dr. Eva Andreuzzi

Email: eva.andreuzzi@burlo.trieste.it

Affiliation: Obstetrics and Gynecology, Institute for Maternal and Child Health - IRCCS "Burlo Garofolo", Trieste, 34137, Italy

Homepage:

Research Interests: tumor microenvironment, cancer, extracellular matrix, chemoresistance


Dr. Albina Fejza

Email: albinafejza@gmail.com

Affiliation: UBT-Higher Education Institution, Kalabria, 10000, Kosovo

Homepage:

Research Interests: tumor microenvironment, cancer, immunotherapy, extracellular matrix


Summary

The tumor microenvironment (TME) plays a crucial role in cancer progression, metastasis, and resistance to therapy, prompting a shift in focus from targeting cancer cells alone to addressing the complex network of surrounding components that support tumor growth. This network involves various players, such as immune cells, cancer-associated fibroblasts (CAFs), blood vessels, the extracellular matrix (ECM), and diverse signaling molecules. All these elements are highly exploited by tumor cells. T cells and macrophages are targeted and manipulated by cancer cells to evade immune responses, making immunotherapies like checkpoint inhibitors essential for restoring immune function.


Meanwhile, cancer-associated fibroblasts (CAFs) contribute to ECM remodeling, metastasis, and drug resistance. On the other hand, angiogenesis is pivotal for supplying tumors with oxygen and nutrients, making anti-angiogenic therapies crucial for cutting off this support. Additionally, hypoxic conditions within tumors drive metabolic adaptations that promote survival, creating opportunities to target altered metabolic pathways. The dense ECM also acts as a physical barrier to therapy, and strategies to modify or degrade it are under investigation to enhance drug delivery.


Considering these facts, emerging therapeutic approaches now aim to simultaneously target multiple aspects of the TME—such as immune modulation, vascular disruption, and ECM alteration—offering a more comprehensive and personalized strategy to combat cancer.


Keywords

cancer, tumor microenvironment, chemoresistance

Published Papers


  • Open Access

    ARTICLE

    PSMD2-Mediated MAPK Signaling Promotes Bladder Cancer Development and Immune Microenvironment Remodeling

    Shuwen Sun, Jingcheng Zhang, Zongtai Zheng, Yajuan Hao, Tianyuan Xu, Ji Liu, Liang Sun, Aimin Wang, Yadong Guo, Shiyu Mao, Xu Zhang, Yunfei Xu, Yifan Chen, Yang Yan
    Oncology Research, DOI:10.32604/or.2025.072373
    (This article belongs to the Special Issue: Targeting the Tumor Microenvironment: Emerging Insights into Cancer Progression and Therapeutics)
    Abstract Objectives: Bladder cancer (BCa) progression is closely linked to the immune microenvironment. However, the key molecules that regulate this microenvironment and their specific mechanisms remain poorly understood. This study aims to identify a key molecule and elucidate its mechanisms, providing a theoretical basis for identifying novel therapeutic targets. Methods: Immune microenvironment-related genes in BCa were identified using The Cancer Genome Atlas and Shanghai Tenth People’s Hospital datasets. Proteasome 26S subunit non-ATPase 2 (PSMD2) expression was validated via quantitative polymerase chain reaction (qPCR), Western blot (WB) analysis, and immunofluorescence (IF). In vitro and in vivo experiments confirmed the… More >

    Graphic Abstract

    PSMD2-Mediated MAPK Signaling Promotes Bladder Cancer Development and Immune Microenvironment Remodeling

  • Open Access

    REVIEW

    Understanding the Tumor Microenvironmental Mechanisms Driving Immunotherapy Resistance in Colorectal Cancer Liver Metastases

    Candela Cives-Losada, Cristiana Soldani, Michela Anna Polidoro, Barbara Franceschini, Ana Lleo, Marcello Di Martino, Matteo Donadon
    Oncology Research, DOI:10.32604/or.2025.074093
    (This article belongs to the Special Issue: Targeting the Tumor Microenvironment: Emerging Insights into Cancer Progression and Therapeutics)
    Abstract Colorectal cancer (CRC) is the second deadliest cancer worldwide, being the presence of metastasis, mainly in the liver, a major contributor to high mortality rates in affected patients. The tumor microenvironment (TME)—comprised of interacting endothelial, stromal, and immune cells—plays a critical role in creating a supportive niche for tumor cell colonization and immune evasion and, thus, the establishment of metastases. The liver’s intrinsic nature further facilitates the development of immune tolerance, mediated by regulatory T cells, myeloid-derived suppressor cells, and soluble factors such as anti-inflammatory cytokines, which together dampen antitumor immune responses. This immunosuppressive milieu More >

    Graphic Abstract

    Understanding the Tumor Microenvironmental Mechanisms Driving Immunotherapy Resistance in Colorectal Cancer Liver Metastases

  • Open Access

    ARTICLE

    SDHA Deficiency in Hepatocellular Carcinoma Promotes Tumor Progression through Succinate-Induced M2 Macrophage Polarization

    Xinyang Li, Luyuan Ma, Chuan Shen, Ruolan Gu, Shilong Dong, Mingjie Liu, Ying Xiao, Wenpeng Liu, Yuexia Liu, Caiyan Zhao
    Oncology Research, DOI:10.32604/or.2025.073179
    (This article belongs to the Special Issue: Targeting the Tumor Microenvironment: Emerging Insights into Cancer Progression and Therapeutics)
    Abstract Background: Hepatocellular carcinoma (HCC) is an aggressive and lethal malignancy. Metabolic reprogramming dynamically remodels the tumor microenvironment (TME) and drives HCC progression. This study investigated the mechanism through which metabolic reprogramming remodels the TME in HCC. Methods: HCC patient transcriptome data were subjected to bioinformatics analysis to identify differentially expressed genes and immune infiltration status. Immunohistochemical analysis was performed to determine the correlation between succinate dehydrogenase complex subunit A (SDHA) expression and M2 macrophage infiltration. SDHA-knockdown or SDHA-overexpressing HCC cells were used for in vitro experiments, including co-culturing, flow cytometry, and enzyme-linked immunosorbent assay. Western blotting… More >

  • Open Access

    REVIEW

    Branched-Chain Amino Acid Metabolic Reprogramming and Cancer: Molecular Mechanisms, Immune Regulation, and Precision Targeting

    Dongchi Cai, Jialin Ji, Chunhui Yang, Hong Cai
    Oncology Research, Vol.34, No.1, 2026, DOI:10.32604/or.2025.071152
    (This article belongs to the Special Issue: Targeting the Tumor Microenvironment: Emerging Insights into Cancer Progression and Therapeutics)
    Abstract Metabolic reprogramming involving branched-chain amino acids (BCAAs)—leucine, isoleucine, and valine—is increasingly recognized as pivotal in cancer progression, metastasis, and immune modulation. This review comprehensively explores how cancer cells rewire BCAA metabolism to enhance proliferation, survival, and therapy resistance. Tumors manipulate BCAA uptake and catabolism via high expression of transporters like L-type amino acid transporter 1 (LAT1) and enzymes including branched chain amino acid transaminase 1(BCAT1), branched chain amino acid transaminase 2 (BCAT2), branched-chain alpha-keto acid dehydrogenase (BCKDH), and branched chain alpha-keto acid dehydrogenase kinase (BCKDK). These alterations sustain energy production, biosynthesis, redox homeostasis, and oncogenic… More >

Share Link